TY  - JOUR
AU  - Vishwanathan, Karthick
AU  - Sanchez-Simon, Inmaculada
AU  - Keam, Bhumsuk
AU  - Penel, Nicolas
AU  - de Miguel-Luken, Maria
AU  - Weilert, Doris
AU  - Mills, Andrew
AU  - Marotti, Marcelo
AU  - Johnson, Martin
AU  - Ravaud, Alain
PY  - 2020
DO  - 10.1002/prp2.613
UR  - http://hdl.handle.net/10668/15791
T2  - Pharmacology research & perspectives
AB  - Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small...
LA  - en
KW  - epidermal growth factor receptors
KW  - kidney
KW  - non-small cell lung cancer
KW  - osimertinib
KW  - pharmacokinetics
KW  - renal disposition
KW  - tyrosine kinase inhibitors
KW  - Acrylamides
KW  - Administration, Oral
KW  - Aged
KW  - Aged, 80 and over
KW  - Aniline Compounds
KW  - Antineoplastic Agents
KW  - Area Under Curve
KW  - Female
KW  - Hepatic Insufficiency
KW  - Humans
KW  - Kidney Function Tests
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Protein Kinase Inhibitors
KW  - Severity of Illness Index
TI  - A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
TY  - research article
VL  - 8
ER  -